$16.29
2.16% day before yesterday
Nasdaq, Dec 27, 09:46 pm CET
ISIN
US0352551081
Symbol
ANIK
Sector
Industry

Anika Therapeutics, Inc. Stock price

$16.24
-1.48 8.35% 1M
-9.48 36.86% 6M
-6.42 28.33% YTD
-6.45 28.43% 1Y
-21.35 56.80% 3Y
-36.59 69.26% 5Y
-23.60 59.24% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.41 2.46%
ISIN
US0352551081
Symbol
ANIK
Sector
Industry

Key metrics

Market capitalization $237.84m
Enterprise Value $203.00m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.24
P/S ratio (TTM) P/S ratio 1.45
P/B ratio (TTM) P/B ratio 1.33
Revenue growth (TTM) Revenue growth 0.52%
Revenue (TTM) Revenue $164.17m
EBIT (operating result TTM) EBIT $-31.41m
Free Cash Flow (TTM) Free Cash Flow $-810.00k
Cash position $62.37m
EPS (TTM) EPS $-6.64
P/E forward negative
P/S forward 1.58
EV/Sales forward 1.35
Short interest 3.61%
Show more

Is Anika Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Anika Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Anika Therapeutics, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Anika Therapeutics, Inc. forecast:

Buy
100%

Financial data from Anika Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
164 164
1% 1%
100%
- Direct Costs 84 84
35% 35%
51%
80 80
21% 21%
49%
- Selling and Administrative Expenses 70 70
14% 14%
43%
- Research and Development Expense 30 30
7% 7%
19%
-21 -21
49% 49%
-13%
- Depreciation and Amortization 10 10
37% 37%
6%
EBIT (Operating Income) EBIT -31 -31
3% 3%
-19%
Net Profit -98 -98
297% 297%
-59%

In millions USD.

Don't miss a Thing! We will send you all news about Anika Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anika Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also par...
Neutral
GlobeNewsWire
about one month ago
BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences.
Neutral
Seeking Alpha
about 2 months ago
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - President and CEO Steve Griffin - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome t...
More Anika Therapeutics, Inc. News

Company Profile

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Head office United States
CEO Cheryl Blanchard
Employees 357
Founded 1992
Website www.anika.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today